How China’s drive to develop its own state-of-the-art Covid vaccine is going

China has yet to approve any mRNA vaccines, which have the highest efficacy rates, despite the recent surge in cases in Shanghai. The authorities have not explained the delay, even though Fosun Pharmaceuticals has a commercial deal to distribute 100 million doses of BioNTech’s vaccine. Many analysts believe the authorities are waiting for a home-grown mRNA vaccine to be developed. Here is what we know so far about that quest.